To finish the continuum of the journey of cancer research, the National Foundation for Cancer Research provides access to several clinical trials that we are in close association with.
Patients can obtain important information on the trials, criteria for enrollment, and contact information.
The GBM AGILE platform trial is for newly diagnosed or recurrent glioblastoma. The Phase II/III clinical study efficiently tests multiple drugs and drug combinations simultaneously.
There are more than 38 GBM AGILE sites in the U.S., with more coming in the near future, as well as many in Canada, Europe, and elsewhere. If you or someone you know may be interested in participating in GBM AGILE, you can locate a trial site and learn how to connect with one of its team members for evaluation and enrollment support by visiting here.
NFCR offers Cancer Patient Treatment Assistance, where patients and families can connect with a professional oncologist to discuss a diagnosis, treatment options and clinical trials. To lean more, including how to access this service, visit here.
